Saint Luke's Health System, Department of Radiology, Saint Luke's Hospital and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Saint Luke's Health System, Department of Radiology, Saint Luke's Hospital and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
J Vasc Interv Radiol. 2019 Sep;30(9):1370-1375. doi: 10.1016/j.jvir.2019.05.024. Epub 2019 Jul 30.
To report initial experience with safety and efficacy in the treatment of pulmonary embolism (PE) using the FlowTriever device.
A single-center retrospective study was performed in all patients with acute central PE treated using the FlowTriever device between March 2018 and March 2019. A total of 46 patients were identified (massive = 8; submassive = 38), all with right ventricular (RV) strain and 26% with thrombolytic contraindications. Technical success (according to SIR reporting guidelines) and clinical success (defined as mean pulmonary artery pressure intraprocedural improvement) are reported, as are major device and procedure-related complications within 30 days after discharge.
Technical success was achieved in 100% of cases (n = 46). Average mean pulmonary artery pressure improved significantly from before to after the procedure for the total population (33.9 ± 8.9 mm Hg before, 27.0 ± 9.0 mm Hg after; P < .0001; 95% confidence interval [CI], 5.0-8.8), submassive cohort (34.7 ± 9.1 mm Hg before, 27.4 ± 9.2 mm Hg after; P < .0001; 95% CI, 5.2-9.5) and massive cohort (30.4 ± 6.9 mm Hg before, 25.4 ± 8.2 mm Hg after; P < .05; 95% CI:0.4-9.6). Intraprocedural reduction in mean pulmonary artery pressure was achieved in 88% (n = 37 of 42). A total of 100% of patients (n = 46 of 46) survived to hospital discharge. In total, 71% of patients (n = 27 of 38) experienced intraprocedural reduction in supplemental oxygen requirements. Two major adverse events (4.6%) included hemoptysis requiring intubation, and procedure-related blood loss requiring transfusion. No delayed procedure-related complications or deaths occurred within 30 days of hospital discharge.
Initial clinical experience using the FlowTriever to perform mechanical thrombectomy showed encouraging trends with respect to safety and efficacy for the treatment of acute central, massive, and submassive pulmonary embolism.
报告使用 FlowTriever 装置治疗肺栓塞(PE)的安全性和疗效的初步经验。
对 2018 年 3 月至 2019 年 3 月期间使用 FlowTriever 装置治疗的所有急性中央型 PE 患者进行了单中心回顾性研究。共确定了 46 例患者(大块型=8 例;次大块型=38 例),所有患者均存在右心室(RV)应变,其中 26%存在溶栓禁忌证。报告了技术成功率(根据 SIR 报告指南)和临床成功率(定义为术中平均肺动脉压的改善),以及出院后 30 天内主要器械和程序相关并发症。
技术成功率为 100%(n=46)。总人群的平均肺动脉压在术前和术后均有显著改善(术前 33.9±8.9mmHg,术后 27.0±9.0mmHg;P<0.0001;95%置信区间[CI],5.0-8.8),次大块型亚组(术前 34.7±9.1mmHg,术后 27.4±9.2mmHg;P<0.0001;95%CI,5.2-9.5)和大块型亚组(术前 30.4±6.9mmHg,术后 25.4±8.2mmHg;P<0.05;95%CI:0.4-9.6)。术中平均肺动脉压降低 88%(n=42,37 例)。所有患者(n=46,46 例)均存活至出院。总共有 71%的患者(n=38 例中的 27 例)术中吸氧需求减少。共有 2 例主要不良事件(4.6%),包括需要插管的咯血和需要输血的与操作相关的失血。出院后 30 天内无迟发性与操作相关的并发症或死亡。
使用 FlowTriever 进行机械血栓切除术的初步临床经验显示,在治疗急性中央型、大块型和次大块型肺栓塞方面具有令人鼓舞的安全性和疗效趋势。